Navigation Links
InterMune to Present at Deutsche Bank Biotech Confab
Date:12/11/2009

BRISBANE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and has submitted a New Drug Application (NDA) to the FDA. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (RG7227) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
2. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
3. InterMune to Present at JMP Securities Conference
4. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
5. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
6. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
7. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. InterMune Announces Progress on Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 In today,s increasingly global ... presence to reflect the needs of a global ... meet the needs of key stakeholders while recognizing ... According to recent research by benchmarking firm, ... participating companies averaged more than $100,000 in annual ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... SAN DIEGO , Dec. 18, 2014  RESMED INC. ... report its second quarter of fiscal year 2015 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 The ... PALS, BLS and ACLS online certification provider, are proud ... http://www.acls-pals-bls.com . The updated site now features a more ... than ever to use. , As a company ... information is now consolidated into a single page during ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... 22, 2014 Physicians in China are ... the treatment of non-Hodgkin’s lymphoma (NHL), according to a ... global healthcare consulting firm. MabThera is the only biologic ... most common form of NHL. , According to Kantar ... the incidence of NHL in China has been growing ...
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 2014 In recognition of Veteran’s Day, ... Hero Reward, a local organization that provides services to ... , Located on a couple hundred acres in the ... lodging, world class fishing, hunting, hiking, horseback riding, 4-wheeling, ... several years ago to support U.S. Service men and ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2
... is expanding its advanced mobile health screening services ... screening equipment and techniques in the industry, HealthYes! screens its ... aortic aneurysm, peripheral artery disease and osteoporosis. , ... ...
... & Liber LLP have been named 2009 Ohio Super Lawyers ... recognizes the law firm,s expertise in personal injury cases and as ... ... Cleveland, Ohio (PRWEB) March 4, 2009 -- Five Cleveland lawyers representing ...
... cervical cancer may direct more women to optimal ... morbidity and complications of trimodality therapy (surgery followed ... the Institute for Technology Assessment in Boston, MA. ... a decision-analytic model to determine the value of ...
... of trauma patients who undergo CT evaluation have incidental ... Corp. at Grant Medical Center in Columbus, OH. ... concern for physicians in regards to the diagnosis and ... out of 1,256 patients (18.3%) who underwent CT of ...
... York, NY (March 3, 2009) A study published in ... (AJN) found that almost 40% of nurses who were ... of misconduct between 2001 and 2005. Nurses on probation ... to recidivate, suggesting that licensing boards should carefully screen and ...
... published in the Journal of Clinical Endocrinology & ... associate professor of clinical medicine and director of the ... increasingly common with age. An estimated 37 million Americans ... of that population. Another 20 to 30 percent of ...
Cached Medicine News:Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 2Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 3Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 3Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 4Health News:MRI and PET/CT improve cervical cancer patient's chances for optimal treatment 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 3Health News:'Pre-diabetics' face heightened risk of heart disease 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: